Joins Nominees for Best New Drug Discovery & Development Product 2017
We were honored recently to have NanoBRET™ Target Engagement Intracellular Kinase Assays nominated by SelectScience® as one of the Best New Drug Discovery & Development Products of 2017. This is a Scientists’ Choice Award®, an opportunity for scientists like you worldwide to vote for your favorite new drug discovery/development product.
We are super excited about both the nomination and the NanoBRET™ Target Engagement Intracellular Kinase Assay. Here is a little information about the assay.
The NanoBRET™ Target Engagement Intracellular Kinase Assay is a first-of-its-kind assay that enables researchers to quantitatively measure test compound binding at full-length kinase targets in live cells. The NanoBRET™ Target Engagement Assay measures the apparent affinity of test compounds by competitive displacement of the NanoBRET™ Tracer, reversibly bound to a NanoLuc® luciferase-kinase fusion in cells, as shown in this diagram.
See a Recent Publication
This recent publication in Cell Chemical Biology provides a more in-depth view on NanoBRET™ Target Engagement (TE) Intracellular Kinase Assays: “Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement”.
To encourage you to vote, SelectScience® is offering this incentive: All scientists who vote are entered into a drawing for a chance to win a $500/£400/450€ Amazon voucher.
Are you ready? Here is the list of nominees and your opportunity to vote. Voting closes on January 29, 2018. Don’t miss this chance to participate in the Scientists’ Choice Awards!
More NanoBRET™ Target Engagement Resources
We are hosting a webinar on January 23 that is now open for registration:
The following links provide more detailed information on NanoBRET™ products and resources:
Latest posts by Kari Kenefick (see all)
- Real-Time Analysis for Cell Viability, Cytotoxicity and Apoptosis: What Would You Do with More Data from One Sample? - January 25, 2022
- Evidence of Inflammasome Activation in Severe COVID-19 - September 22, 2021
- Psilocybin as Antidepressant: Quick Acting, Lasting Benefits - August 20, 2021